Back to Search
FRANCISCO ESTEVA, M.D., PHD
M.D., PHD
Medical Oncology Physician
NPI: 1609974245IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
272572(NY)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
OTHER
Class of 1992
Research & Publications (20)
Survival among women with triple receptor-negative breast cancer and brain metastases.
PMID 19150943·Ann Oncol·2009
8-other
Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations.
PMID 19147689·Oncologist·2009
6-review
Topoisomerase II{alpha} amplification and anthracycline-based chemotherapy: the jury is still out.
PMID 19470912·J Clin Oncol·2009
8-other
Phase I study of prolonged-infusion gemcitabine combined with cyclophosphamide in patients with metastatic carcinoma of the breast: tolerability of an optimal dose schedule.
PMID 19556811·Oncology·2009
3-trial
Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer.
PMID 19252432·Am J Surg Pathol·2009
8-other
Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer.
PMID 19664181·Breast Cancer Res·2009
6-review
Residual risk of breast cancer recurrence 5 years after adjuvant therapy.
PMID 18695137·J Natl Cancer Inst·2008
8-other
Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.
PMID 19047121·Clin Cancer Res·2008
3-trial
Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer.
PMID 19034632·J Mammary Gland Biol Neoplasia·2008
6-review
DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight.
PMID 18628296·Nucleic Acids Res·2008
8-other
Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer.
PMID 18410797·Semin Oncol·2008
6-review
Commentary: can circulating HER-2 extracellular domain predict response to trastuzumab in HER-2-negative breast cancer?
PMID 18448550·Oncologist·2008
8-other
Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells.
PMID 18644997·Mol Cancer Ther·2008
8-other
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.
PMID 18667396·Ann Oncol·2008
4-observational
Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.
PMID 18661530·Cancer·2008
4-observational
Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer.
PMID 19091778·Oncologist·2008
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 160 E 34TH ST
NEW YORK, NY 10016 - Phone
- (212) 731-5657
Quick Facts
- NPI
- 1609974245
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 34
- Publications
- 20
Are you this provider?
Claim Your Profile